[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gonorrhea\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gonorrhea":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,44,73,107,132,158,189,217,241,273,303],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100644627","metagenomic-analysis-of-the-pharynx-in-high-risk-partners-100644627",false,"NCT07671014","Metagenomic Analysis of the Pharynx in High Risk Partners","A Preliminary Investigation to Determine the Utility of Using Metagenomic Analysis of Pharyngeal Samples Taken From Partners of Patients Diagnosed With Gonorrhoea to Identify Organisms, Antibiotics Resistance and Virulence Factors of Neisseria Species and the Impact of STI Prevention Strategies (4CMenB Vaccination and DoxyPEP)","Inclusion Criteria:\n\n* Partner alerted of their risk about being a partner of someone diagnosed with Neisseria Gonorrhea using the digital partner notification software SXT and then booking an appointment for standard of care testing.\n\nExclusion Criteria:\n\n* Under 18 years, unable to speak English","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","The Neisseria gonorrhoea (NG) epidemic in England is at the highest level in one hundred years of public health records. The World Health Organisation has listed NG as one of the top five bacterial infections globally because of the ability of the bacteria to develop resistance to antibiotics. Neisseria meningitidis (NM) is a common pharyngeal commensal and it has been shown to be in one in five men who have sex with men (MSM) in London.\n\nIn the last year sexual health clinics have had a growing number of MSM presenting with urethritis \u002F proctitis that were treated for NG on the day only to be found later to have been infected with NM from the culture. It appear that virulence factors have been passed from NG to NM enabling these bacteria to infect the urogenital and anal mucosa; consequently, NM in some cases is a new Sexually Transmitted Infection (STI). In 2025, two STI prevention interventions were rolled out in an attempt to address the gonorrhoea \\& syphilis epidemics and these were the 4CMenB vaccine and doxycycline post exposure prophylaxis (DoxyPEP).\n\nThis study will recruit sexual partners of patients who have been diagnosed with NG and the investigators will ask the participant for one additional pharyngeal sample for research that will not impact on their standard of care. The additional sample will be tested using metagenomics, that is where all non-human DNA is analysed, and the initial focus will be on NG or NM infection, co-infection, genes for virulence and antibiotic resistance from whole genome sequencing.\n\nThe metagenomic analysis is being undertaken for research purpose only; however, secondary outcomes will look for other STIs in the pharyngeal sample and sample turn around time to inform the management of patients. Any additional STI identified will have validated testing to confirm diagnosis.",[24,25,26,27],"Gonorrhea","Neisseria Gonorrhea","Neisseria Meningitidis","Metagenomic Next Generation Sequencing",[24,29,30,31],"Metagenomic testing","Neisseria Gonorrhoea","Neisseria Meningitis","NOT_YET_RECRUITING","2026-06-26",{"date":35,"type":36},"2026-06-30","ACTUAL",{"date":38,"type":20},"2026-07-14",{"date":40,"type":20},"2027-02-28",{"name":42,"class":43},"Guy's and St Thomas' NHS Foundation Trust","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100628637","improving-clinic-delivery-of-hiv-related-anal-health-services-100628637","NCT07464236","Improving Clinic Delivery of HIV-related Anal Health Services","Partnering to Enhance Anal Health Communication and HIV-related Evidence-based Services","PEACHES 2","Inclusion Criteria:\n\nStaff participants (\"Strategy Recipients\" and \"Strategy Recipients\")\n\n* employed at one of eight Coastal Family Health Center clinics at the time of the survey\n* over age 18 years old\n\nPatient participants (\"Patients\")\n\n* accessing sexual health services at one of eight Coastal Family Health Center clinics in the last 12 months\n* over 18 years old\n\nExclusion Criteria:\n\n* Staff or patients who are unable to provide informed consent (e.g., significant cognitive impairment)\n* Individuals currently incarcerated or in state custody\n* Patients whose only visits are for non-HIV, non-STI issues and who do not meet the EMR-based eligibility criteria above",true,{"count":54,"type":20},8,"INTERVENTIONAL",[57],"NA","This project will test ways to reduce stigma in healthcare settings so that more providers offer, and more patients receive, important anal sex-related HIV services, including anorectal sexually transmitted infection (STI) testing, preventive medications, and cancer screening. By evaluating these stigma-reduction strategies in eight clinics in the Mississippi Delta, a region with high rates of HIV and STIs, the research team will learn whether and how these approaches work to improve access to care. The results will help guide healthcare systems in using the most effective methods to reduce stigma, making it easier for people to get prevention services and improving public health.",[60,24,61,62],"HIV","Chlamydia","Anal Cancer Squamous Cell","2026-06-02",{"date":65,"type":36},"2026-06-03",{"date":67,"type":20},"2026-08-01",{"date":69,"type":20},"2030-07-31",{"name":71,"class":43},"Albert Einstein College of Medicine",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":55,"phases":85,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":106},"100572833","phase-4-doxycycline-prophylaxis-for-prevention-of-sexually-transmitted-infections-100572833","NCT06738407","Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections","Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections Among Adolescent and Young Adult Females in the United States","Inclusion Criteria:\n\n* Age 13-29 years, inclusive;\n* Self-reports GC, CT, and\u002For early syphilis diagnosis in the 12 months prior to screening;\n* Self-reports condomless (oral, vaginal, and\u002For anal) intercourse at least once in the 30 days prior to screening\n* Is at least 45 kilograms (99.2 pounds) in weight\n* Fluent in English (able to read, speak, and understand English);\n* Willing to undergo all required study procedures; and\n* Willing to provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Is male;\n* Is pregnant, breastfeeding, or planning to become pregnant in the next 12 months;\n* Documented history of tetracycline allergy or self-reports an allergy to tetracyclines;\n* Current or anticipated use of a medication (e.g., barbiturates, phenytoin, lithium, carbamazepine, systemic retinoids, warfarin) with a contraindicated interaction to doxycycline ;\n* Current or planned use of doxycycline for a prolonged period (\\> 2 weeks) in the 30 days prior to enrollment, including current prescription for doxycycline for STI prophylaxis;\n* Prolonged antibiotic use (\\> 2 weeks) within the last 30 days prior to enrollment;\n* Co-enrollment in any other concurrent interventional research or studies that may interfere with this study, such as an STI prevention trial, unless approved by Protocol Team in writing;\n* Does not have consistent access (or anticipated weekly access for 52 weeks of survey completion) to smartphone that can access the HMP app; or\n* Any other medical condition, medical\u002Fbehavioral intervention, or other conditions that, in the opinion of the clinical site Project Lead (PL)\u002FInvestigator of Record (IoR) or designee, could interfere with adherence to study procedures or compromise interpretation of study results.","FEMALE","13 Years","29 Years",{"count":84,"type":20},760,[86],"PHASE4","The goal of this open-label, randomized trial is to assess the efficacy of doxycycline prophylaxis in reducing incidences of bacterial sexually transmitted infections (STIs) among adolescent and young adult females while also evaluating acceptability and antimicrobial resistance in order to inform public health policy.",[24,61,89,90],"Syphilis","Sexually Transmitted Infections (STIs)",[92,93,94,95],"Sexually Transmitted Infections","STIs","Doxycycline Prophylaxis","Doxycycline","RECRUITING","2026-05-12",{"date":99,"type":36},"2026-05-15",{"date":101,"type":36},"2026-02-27",{"date":103,"type":20},"2028-06-15",{"name":105,"class":43},"Westat",13,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":52,"sex":16,"minAge":115,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":55,"phases":119,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":72},"100491394","effectiveness-of-relationship-education-for-reducing-hiv-incidence-among-men-who-have-sex-with-men-100491394","NCT05678556","Effectiveness of Relationship Education for Reducing HIV Incidence Among Men Who Have Sex With Men","Effectiveness of Relationship Education for Reducing HIV Incidence in Men Who Have Sex With Men","all2GETHER","Inclusion Criteria:\n\n* Cisgender men, transgender women and men, non-binary individuals\n* Had condomless anal sex with 2 or more serodiscordant\u002Funknown-status cisgender male partners in the last 6 months\n* Aged 16-34 years\n* Lab-test confirmed HIV-negative\n* Read and speak English at 8th grade level or better\n* Internet access\n* Agree to audio recording of intervention sessions\n* Provides address to receive HIV\u002FSTI test supplies\n* For dyads, both partners may enroll if they meet the above criteria- partners who are aged 35+ and\u002For HIV-positive may enroll in a more limited capacity\n\nExclusion Criteria:\n\n-Participants assigned female at birth who identify as women are not eligible","16 Years","34 Years",{"count":118,"type":20},5000,[57],"The purpose of this study is to upgrade an existing relationship education and HIV prevention program. This program is designed for gay, bisexual, queer, and transgender and non-binary people who partner with cisgender men. This means the program is designed for gay, bisexual and queer men, including both cisgender and transgender men. It is also designed for transgender and non-binary people who partner with cisgender men, including both transfeminine and transmasculine people. The investigators aim to test the effectiveness of this updated program among couples and single people.\n\nParticipants will complete online surveys and get tested for Chlamydia and Gonorrhea. Participants will be tested for urethral and rectal Chlamydia and Gonorrhea. Participants will also complete at-home point-of-care HIV testing, with confirmatory testing for preliminary positive results. They will also participate in our program on relationship education and HIV prevention. Study staff will follow up with participants for up to 2 years.\n\nAll participants will be randomized into one of two different conditions: the all2GETHER program or no program. \"Randomized\" means that it is completely up to chance which condition participants will be put into. Participants have a 50% chance of being assigned to either condition, similar to a coin toss. Participants should expect that they will be in this research study for 2 years. Participation in this study will be done remotely - participants will never need to come into a research lab.",[122,61,24],"Hiv","2026-05-06",{"date":125,"type":36},"2026-05-08",{"date":127,"type":36},"2022-12-15",{"date":129,"type":20},"2028-08-31",{"name":131,"class":43},"Northwestern University",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":52,"sex":16,"minAge":139,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":55,"phases":143,"briefSummary":144,"conditions":145,"keywords":146,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":72},"100549025","a-seek-test-and-treat-intervention-to-reduce-chlamydia-trachomatis-disparities-100549025","NCT06428643","A Seek, Test, and Treat Intervention to Reduce Chlamydia Trachomatis Disparities","A Seek, Test, and Treat Intervention to Reduce Chlamydia Trachomatis Disparities in Black Youth Living in the Deep South","Inclusion Criteria:\n\n* Identifies as African American or Black\n* 15-26 years of age\n* Lives or spends most of their time in Orleans Parish\n* Had vaginal sex at least once\n\nExclusion Criteria:\n\n* Unwilling or unable to provide informed consent\n* Unable to speak or understand English\n* Previously enrolled in the study\n* Known to be pregnant\n* Known HIV positive status","15 Years","26 Years",{"count":142,"type":20},2322,[57],"This study includes testing for four STIs (chlamydia, gonorrhea, syphilis, and HIV) at no cost. If positive, individual subjects will also be counseled and offered options for treatment for themselves and their sex partners that may include no cost expedited treatment and the option to be rescreened 3 months after treatment.",[61,24,122,89],[147,148],"Screening","Expedited Treatment","2026-04-30",{"date":151,"type":36},"2026-05-05",{"date":153,"type":36},"2025-08-14",{"date":155,"type":20},"2029-09-01",{"name":157,"class":43},"Tulane University",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":55,"phases":167,"briefSummary":168,"conditions":169,"keywords":175,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":72},"100574980","integrated-care-versus-usual-care-for-opioid-use-disorder-and-infectious-diseases-in-veterans-100574980","NCT06766331","Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans","Integrating Infectious Diseases Screening and Treatment With Medication Assisted Therapy for Veterans With Opioid Use Disorder","Inclusion Criteria:\n\n* US Veteran\n* Able to provide written informed consent in English\n* Living in the community (Nassau, Suffolk, Kings, Queens, Bronx, Westchester, Rockland counties, NY)\n* Documented diagnosis of moderate to severe opioid use disorder\n* Seeking care at the Northport VA substance use disorder clinic for opioid use disorder treatment\n* Willing to have HIV, HBV, HCV, or bacterial STI testing to determine negative or positive status\n* Persons who test negative for HIV need to meet CDC PrEP eligibility criteria in the 6 months prior to enrollment\n\nExclusion Criteria:\n\n* Severe medical or psychiatric disability making participation unsafe\n* Unable to provide written consent\n* PrEP exclusion: HIV positive test; HBV positive test",{"count":166,"type":20},60,[57],"Opioid use disorder (OUD) confers a higher risk of acquiring and transmitting infectious diseases, which may have long-term health consequences in Veterans. Treatment of OUD with medication assisted therapy is highly effective, however this often occurs independently of infectious diseases care. This project will test out a new model that combines infectious diseases and OUD care within one VA clinic appointment. This new care model may improve the health of Veterans and reduce cost and time required for Veterans who often need to attend multiple outpatient appointments.",[170,60,171,24,61,89,172,173,174],"Opioid Use Disorder","Hepatitis C Virus","Sexually Transmitted Infection","Integrated Care","Medications for Opioid Use Disorder",[176,60,177,178],"Hepatitis C","sexually transmitted diseases","Opioid-Related Disorders","2026-04-21",{"date":181,"type":36},"2026-04-24",{"date":183,"type":20},"2028-04-03",{"date":185,"type":20},"2029-06-29",{"name":187,"class":188},"VA Office of Research and Development","FED",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":52,"sex":16,"minAge":115,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":199,"conditions":200,"keywords":203,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":4},"100632686","evaluation-of-free-sti-testing-pilot-projects-in-lucerne-and-zurich-switzerland-100632686","NCT07516912","Evaluation of Free STI Testing Pilot Projects in Lucerne and Zurich, Switzerland","feSTI: Evaluation of Free HIV and STI Testing and Counselling Services for Young and Disadvantaged Populations in Lucerne and Zurich","feSTI","Inclusion Criteria:\n\n* taking part in the pilot programmes\n* understand the study information\n* 16 years of age or older\n\nExclusion Criteria:\n\n* not eligible for the pilot programmes\n* not understanding the study information\n* less than 16 years old",{"count":198,"type":20},1800,"The main goal of the observational study is to evaluate participants' satisfaction with free HIV and sexually transmitted infection (STI) testing and counselling offered by the cities of Lucerne and Zurich, Switzerland to young people and people with low incomes. Counselling and testing can be accessed without participating in the study arm of the project.",[201,61,24,89,202],"HIV (Human Immunodeficiency Virus)","HCV",[204,205,60,206,207],"Voluntary counselling and testing","sexually transmitted infections","implementation of free testing","barriers to care","2026-04-02",{"date":210,"type":36},"2026-04-08",{"date":212,"type":20},"2026-04-07",{"date":214,"type":20},"2029-02-28",{"name":216,"class":43},"University of Zurich",{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":55,"phases":226,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":72},"100631418","doxi-rio-study-on-the-use-of-doxycycline-to-prevent-sexually-transmitted-infections-in-rio-de-janeiro-100631418","NCT07500415","Doxi-Rio: Study on the Use of Doxycycline to Prevent Sexually Transmitted Infections in Rio de Janeiro","Doxi-Rio: Pilot Implementation of Post-exposure Prophylaxis for Sexually Transmitted Infections With Doxycycline in Rio de Janeiro, Brazil","Inclusion Criteria:\n\n* Individuals assigned male at birth (cisgender or transgender men), transgender women, or travestis who have sex with men\n* Age ≥18 years\n* Living with HIV or currently using HIV pre-exposure prophylaxis (PrEP) for at least 6 months\n* History of at least one bacterial sexually transmitted infection (chlamydia, gonorrhea, or syphilis) in the past 12 months (laboratory-confirmed or self-reported)\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to doxycycline or other tetracycline-class antibiotics\n* Current use of medications that may significantly interact with doxycycline or are contraindicated, including systemic retinoids, barbiturates, carbamazepine, or phenytoin",{"count":225,"type":20},200,[57],"The goal of this clinical trial is to learn if doxycycline post-exposure prophylaxis (doxy-PEP) can help prevent bacterial sexually transmitted infections (STIs) among sexual and gender minorities in Rio de Janeiro, Brazil, including men who have sex with men, transgender women, and travestis who are living with HIV or using HIV pre-exposure prophylaxis (PrEP). Bacterial STIs such as syphilis, gonorrhea, and chlamydia remain common in these populations, even with existing prevention strategies.\n\nThis study aims to answer the following questions: whether doxy-PEP can reduce the number of new STIs, whether it is safe and well tolerated, whether participants use it as recommended, and whether its use may contribute to antibiotic resistance or changes in the body's natural bacteria. Doxy-PEP involves taking a dose of doxycycline, an antibiotic, shortly after sexual activity to reduce the risk of acquiring STIs.\n\nParticipants will first receive information and counseling about doxy-PEP, including its possible benefits and risks, and will then choose whether or not to use this prevention strategy. Those who choose to use doxy-PEP will take doxycycline after sex as instructed and will be followed for up to 48 weeks, with clinic visits approximately every three months. During these visits, participants will be tested for STIs, monitored for side effects, and asked about medication use, sexual health, and overall well-being.\n\nResearchers will collect information on new STI diagnoses, safety, and how consistently participants use doxy-PEP. The study will also explore participants' experiences and perceptions of this strategy. The results of this study will help determine whether doxy-PEP is a practical and acceptable approach for STI prevention in Brazil and may inform future public health strategies.",[229,89,24,230,231],"Sexually Transmitted Diseases","Chlamydia Infections","HIV Infections","2026-03-24",{"date":234,"type":36},"2026-03-30",{"date":236,"type":36},"2025-10-28",{"date":238,"type":20},"2028-05",{"name":240,"class":43},"Oswaldo Cruz Foundation",{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":52,"sex":249,"minAge":250,"maxAge":251,"enrollmentInfo":252,"targetDuration":4,"studyType":55,"phases":254,"briefSummary":255,"conditions":256,"keywords":258,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":72},"100623497","phase-4-the-efficacy-of-doxycycline-post-exposure-prophylaxis-for-preventing-stis-among-msm-in-bangkok-thailand-100623497","NCT07397403","The Efficacy of Doxycycline Post Exposure Prophylaxis for Preventing STIs Among MSM in Bangkok, Thailand.","The Efficacy of Doxycycline Post Exposure Prophylaxis for Preventing Sexually Transmitted Diseases (Gonorrhea, Chlamydia, Syphilis) Among Men Who Have Sex With Men in Bangkok, Thailand.","ThaiDoxyPEP","Inclusion Criteria:\n\nBiological male, aged not over 60 years\n\nThai nationality\n\nAble to read, communicate, and understand the Thai language\n\nMen who have sex with men (MSM), aged 18 years or older and not over 60 years\n\nHaving at least one of the following risk factors:\n\nA history of condomless sex, or condom failure (breakage, leakage, or slippage), via any sexual route with at least two sexual partners within the past 3 months\n\nA diagnosis of gonorrhea, chlamydia, or syphilis within the past 6 months\n\nCurrent use of HIV pre-exposure prophylaxis (PrEP)\n\nWilling and able to participate in study procedures (e.g., able to return to the clinic for scheduled testing for gonorrhea, chlamydia, and syphilis; able to complete doxycycline use records; and able to receive follow-up phone calls from the research team)\n\nWilling and able to provide written informed consent to participate in the study\n\n\\-\n\nExclusion Criteria:\n\n* History of allergy to tetracycline-class antibiotics\n\nDiagnosed with syphilis and not yet treated, or currently receiving treatment with benzathine penicillin G or doxycycline\n\nReceipt of benzathine penicillin G within the past 12 weeks\n\nPrior receipt of a gonorrhea vaccine\n\nCurrent use of medications or products that may interact with doxycycline, including:\n\nVitamin A derivatives (e.g., isotretinoin, acitretin)\n\nAntiepileptic drugs (e.g., phenytoin, carbamazepine, phenobarbital)\n\nImmunosuppressive agents (e.g., methotrexate)\n\nMedications for heart failure or cardiac arrhythmias (e.g., digoxin)\n\nAnticoagulants (e.g., warfarin)\n\nUse of oral or injectable medications that affect blood cells, such as anticancer drugs, chemotherapy, systemic corticosteroids, or targeted therapies\n\nHistory of renal impairment (eGFR \\\u003C 60 mL\u002Fmin\u002F1.73 m²) or hepatic impairment (AST or ALT \\> 3 times the upper limit of normal)\n\nUncontrolled or unstable underlying diseases, such as hematologic disorders, cancer, autoimmune diseases, or neurological disorders\n\nSevere medical or psychiatric conditions that, in the investigator's judgment, may increase study-related risk or impair the participant's ability to provide informed consent\n\nAlcohol dependence (inability to control alcohol consumption, withdrawal symptoms upon reduction or cessation, or continued use despite harm) or illicit drug dependence (regular, uncontrolled use) within the past 12 months prior to enrollment, which may affect doxycycline use for STI prevention\n\nPrevious participation in this study with prior randomization","MALE","18 Days","60 Days",{"count":253,"type":20},400,[86],"The objective of this research is to evaluate the efficacy and safety of doxycycline in MSM for preventing sexually transmitted infections (gonorrhea, chlamydia, and syphilis) in Thailand\n\nParticipation in this study will last approximately 12 weeks and will include 2-3 clinic visits, along with 10-11 follow-up phone contacts over a period of 11 weeks.",[257,24,61],"Syphilis Infection",[259,260,89,261,61,262],"DoxyPEP","MSM","gonorrhea","Prevention","2026-02-02",{"date":265,"type":36},"2026-02-09",{"date":267,"type":36},"2025-10-06",{"date":269,"type":20},"2027-05-31",{"name":271,"class":272},"Bangrak STIs Center","OTHER_GOV",{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":279,"eligibilityCriteria":280,"healthyVolunteers":52,"sex":80,"minAge":281,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":55,"phases":284,"briefSummary":285,"conditions":286,"keywords":289,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":301,"locationsCount":72},"100589209","assessing-acceptability-and-feasibiity-of-sti-self-swab-testing-to-be-offered-at-the-time-of-telemed-medication-abortion-provision-100589209","NCT06951438","Assessing Acceptability and Feasibiity of STI Self-swab Testing, to be Offered at the Time of Telemed Medication Abortion Provision","STI Self-swab Testing At the Time of Telemed Medication Abortion Provision","STAMP","Inclusion Criteria:\n\n1. Patients of the Queen Medical Center Options Center clinic seeking telemedicine medication abortion.\n2. Patients for whom, according to the CDC guidelines for STI Testing11, STI testing is indicated, or patients who desire STI screening\n3. Age 14 and over\n4. Can speak and read English\n5. Displays capacity for informed consent\n\nExclusion Criteria:\n\n1. Home address that is not located in the state of Hawai'i\n2. Incarcerated\n3. Unwilling to perform vaginal swab collection","14 Years",{"count":283,"type":20},75,[57],"The goal of this interventional study is to provide more access to STI testing for patients who seek abortion care through telemedicine, particularly for those whose access to STI testing is otherwise limited. The main questions it aims to answer are:\n\nWhat is the acceptability, feasibility, and utilization of self-collected STI screening at the time of telemedicine medication abortion provision?\n\nHow does the uptake of such a service among patients receiving telemedicine abortion care compare to the population of patients who seek in-person medication abortion care?\n\nWhat are the positivity rates for STIs in among patients receiving telemedicine medication abortion care compared to the positivity rates for a contemporaneous, in-clinic population?\n\nWhat is the average time to between testing and treatment for patients who test positive for an STI using the self-collection service?\n\nResearchers will compare the intervention group to a contemporaneous, in-clinic population on uptake of STI screening, as well as on positivity rates for the STIs tested.\n\nParticipants will be asked to perform self-swab collection for STI testing for gonorrhea, chlamydia, and trichomonas. They will be instructed to send their specimens to a lab using prepaid postage. Upon completion of sample collection and shipping, they will be asked to complete a survey assessing basic demographic information, as well as acceptability and feasibility of the intervention. Patients who test positive for an STI will be promptly provided\u002Freferred to treatment.",[287,24,61,288],"Sexually Transmitted Disease (STD)","Trichomonas Infection",[290,291,292,293,294],"STI testing","telemedicine","medication abortion","self-swab collection","vaginal swab","2025-06-25",{"date":297,"type":36},"2025-06-26",{"date":299,"type":36},"2025-05-22",{"date":35,"type":20},{"name":302,"class":43},"Queen's Medical Center",{"id":304,"slug":305,"hasResults":11,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":309,"eligibilityCriteria":310,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":311,"enrollmentInfo":312,"targetDuration":314,"studyType":21,"phases":4,"briefSummary":315,"conditions":316,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":72},"100464312","vienna-hiv-infection-via-sex-study-100464312","NCT05326061","Vienna HIV Infection Via Sex Study","Characterization of Patients at High Risk for the Acquisition of Sexually Transmitted Infection With the Human Immunodeficiency Virus (HIV) - a Clinical Study","HIVEX","Inclusion Criteria:\n\n1. High risk for acquiring HIV defined as followed: HIV-negative MSM and transgender individuals who (i) do not use condoms consistently with casual partners and\u002For with HIV-positive partners who are not on treatment and\u002For (ii) recently acquired an STI and\u002For (iii) recently used PEP and\u002For (iv) frequently engage in 'chemsex'.\n2. Age \\>18 years and \\\u003C100 years.\n3. Written informed consent for this registry study.\n\nExclusion Criteria:\n\n1\\. Withdrawal of the written informed consent.","100 Years",{"count":313,"type":20},500,"5 Years","The main objective of this prospective observational cohort study is to investigate the epidemiology, the risk factors and ultimately the incidence of novel HIV infections among individuals at high risk for acquiring HIV via sex practices.",[231,317,229,24,61,89],"HIV Pre-Exposure Prophylaxis","2022-04-06",{"date":320,"type":36},"2022-04-13",{"date":322,"type":36},"2020-07-01",{"date":324,"type":20},"2030-12",{"name":326,"class":43},"Medical University of Vienna"]